The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and other ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Hundreds of millions of people around the world live with major depressive disorder (MDD), making it the most commonly diagnosed mental disorder with numbers increasing annually. Past studies show ...

CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to at least two oral ...

CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of: Treatment-Resistant Depression (TRD) in adults, and Major Depressive Disorder (MDD) with acute ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

"A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray ... Care on the Rapid Reduction of Symptoms of Major ...